Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $3.67 Analyst target: $13.47 Upside: 267.03%
Opus Genetics, Inc. (IRD) is a pioneering biotechnology company dedicated to advancing gene therapies for rare retinal diseases that affect vision. Utilizing cutting-edge gene-editing techniques and a strong research framework, Opus Genetics seeks to address significant unmet medical needs in ocular health. The company's innovative pipeline, bolstered by ongoing clinical trials and strategic partnerships, positions it favorably within the dynamic healthcare sector, offering substantial growth potential for institutional investors.
See the full interactive analysis & chart →Informational only — not investment advice.